MedPath

An evaluation of a medicinal herb as a treatment for Parkinson’s disease

Phase 2
Conditions
Parkinson´s disease
Registration Number
RBR-6t4j85
Lead Sponsor
Hospital Universitário Clementino Fraga Filho - UFRJ
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

40 l-dopa treated patients (both genders) with Parkinson’s disease fulfilling the Queen Square Brain Bank Criteria with mild to moderate motor fluctuations will be recruited.

Exclusion Criteria

Demented patients with the Mini Mental Status Examination Score, women of childbearing age and those receiving monoamine oxidase inhibitors or amantidine were excluded.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the safety and descriptive efficacy of Banisteriopsis caapi for the treatment of Parkinson´s disease. Safety will be assessed by means of physical examination and vital signs, collection of adverse events and clinical laboratory tests.Safety results and adverse events will be assessed at every visit.;Change of 5.5 points in total MDS-UPDRS, and MDS-UPDRS motor scores
Secondary Outcome Measures
NameTimeMethod
MDS-UPDRS dyskinesia score and HADS score change.;Reduction in off time calculated using waking day on-off self scoring diaries based on baseline assessment and twice weekly diary measurement for 4 weeks
© Copyright 2025. All Rights Reserved by MedPath